Literature DB >> 34704420

Very long chain acylcarnitines and lysophosphatidylcholines in screening of peroxisomal disease in children by tandem mass spectrometry.

Yanmin Wang1, Guoli Tian1, Wei Ji1, Simei Wang1, Xiaofen Zhang1.   

Abstract

To investigate the value of very long chain acylcarnitine (VLCAC) and lysophosphatidylcholine (LPC) in screening of peroxisomal disease in children. Eighteen children with peroxisomal disease, including 14 cases of X-linked adrenoleukodystrophy (X-ALD group) and 4 cases of Zellweger syndrome (ZS group) diagnosed based on clinical symptoms, MRI and genetic tests were enrolled in the study; and 200 healthy children were selected as control group. Samples of dried blood spots were collected from all subjects, VLCAC and LPC in dried blood spots were extracted by solvent containing internal isotopic standards hexacosanoylcarnitine (H-C26) and C26:0 lysophosphatidylcholine (H-C26:0-LPC). The eicosanoylcarnitine (C20), docosanoylcarnitine (C22), tetracosanoylcarnitine (C24), hexacosanoylcarnitine (C26), C20:0 lysophosphatidylcholine (C20:0-LPC), C22:0 lysophosphatidylcholine (C22:0-LPC), C24:0 lysophosphatidylcholine (C24:0-LPC) and C26:0 lysophosphatidylcholine (C26:0-LPC) were detected by tandem mass spectrometry (MS/MS). The above 8 indicators and the ratios were compared among the groups using Kruskal-Wallis test and Mann-Whitney test; the contribution of each index to the disease were analyzed by partial least square method. Except C24:0-LPC/C20:0-LPC, there were significant differences in all indicators and ratios among all groups (<0.05 or <0.01). There were differences in most indicators and ratios between X-ALD group and the control group, as well as between ZS group and the control group, but there was no difference between the X-ALD group and the ZS group. PLS-DA analysis showed that the peroxisome disease group (including X-ALD group and ZS group) and the control group were able to be completely separated, and C26 had the highest variable importance for the projection (VIP) value. MS/MS detection of VLCAC and LPC can be used as a screening method for peroxisomal disease, and C26 may be a sensitive indicator for diagnosis.

Entities:  

Keywords:  Lysophosphatidylcholine; Peroxisomal disease; Screening; Tandem mass spectrometry; Very long chain acylcarnitine

Mesh:

Substances:

Year:  2021        PMID: 34704420      PMCID: PMC8714475          DOI: 10.3724/zdxbyxb-2021-0254

Source DB:  PubMed          Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban        ISSN: 1008-9292


  16 in total

1.  Combined liquid chromatography-tandem mass spectrometry as an analytical method for high throughput screening for X-linked adrenoleukodystrophy and other peroxisomal disorders: preliminary findings.

Authors:  Walter C Hubbard; Ann B Moser; Silvia Tortorelli; Anita Liu; David Jones; Hugo Moser
Journal:  Mol Genet Metab       Date:  2006-07-07       Impact factor: 4.797

2.  Comparison of C26:0-carnitine and C26:0-lysophosphatidylcholine as diagnostic markers in dried blood spots from newborns and patients with adrenoleukodystrophy.

Authors:  Irene C Huffnagel; Malu-Clair van de Beek; Amanda L Showers; Joseph J Orsini; Femke C C Klouwer; Inge M E Dijkstra; Peter C Schielen; Henk van Lenthe; Ronald J A Wanders; Frédéric M Vaz; Mark A Morrissey; Marc Engelen; Stephan Kemp
Journal:  Mol Genet Metab       Date:  2017-10-28       Impact factor: 4.797

Review 3.  Normal and defective neuronal membranes: structure and function: neuronal lesions in peroxisomal disorders.

Authors:  J M Powers
Journal:  J Mol Neurosci       Date:  2001 Apr-Jun       Impact factor: 3.444

4.  Increased very long chain fatty acids in patients on a ketogenic diet: a cause of diagnostic confusion.

Authors:  C Theda; R C Woody; S Naidu; A B Moser; H W Moser
Journal:  J Pediatr       Date:  1993-05       Impact factor: 4.406

Review 5.  Childhood X-linked adrenoleukodystrophy: clinical-pathologic overview and MR imaging manifestations at initial evaluation and follow-up.

Authors:  Ji Hyung Kim; Hyon J Kim
Journal:  Radiographics       Date:  2005 May-Jun       Impact factor: 5.333

6.  Streamlined determination of lysophosphatidylcholines in dried blood spots for newborn screening of X-linked adrenoleukodystrophy.

Authors:  Coleman T Turgeon; Ann B Moser; Lars Mørkrid; Mark J Magera; Dimitar K Gavrilov; Devin Oglesbee; Kimiyo Raymond; Piero Rinaldo; Dietrich Matern; Silvia Tortorelli
Journal:  Mol Genet Metab       Date:  2014-11-27       Impact factor: 4.797

7.  Rapid stable isotope dilution analysis of very-long-chain fatty acids, pristanic acid and phytanic acid using gas chromatography-electron impact mass spectrometry.

Authors:  P Vreken; A E van Lint; A H Bootsma; H Overmars; R J Wanders; A H van Gennip
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1998-08-25

8.  Evaluation of a panel of very long-chain lysophosphatidylcholines and acylcarnitines for screening of X-linked adrenoleukodystrophy in China.

Authors:  Guo-Li Tian; Feng Xu; Kuan Jiang; Yan-Min Wang; Wei Ji; Ying-Ping Zhuang
Journal:  Clin Chim Acta       Date:  2020-01-21       Impact factor: 3.786

9.  A report on state-wide implementation of newborn screening for X-linked Adrenoleukodystrophy.

Authors:  Katie Wiens; Susan A Berry; Hyoung Choi; Amy Gaviglio; Ashish Gupta; Amy Hietala; Daniel Kenney-Jung; Troy Lund; Weston Miller; Elizabeth I Pierpont; Gerald Raymond; Holly Winslow; Heather A Zierhut; Paul J Orchard
Journal:  Am J Med Genet A       Date:  2019-05-10       Impact factor: 2.802

Review 10.  X-linked adrenoleukodystrophy: Pathology, pathophysiology, diagnostic testing, newborn screening and therapies.

Authors:  Bela R Turk; Christiane Theda; Ali Fatemi; Ann B Moser
Journal:  Int J Dev Neurosci       Date:  2020-01-26       Impact factor: 2.457

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.